Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

18 / 39

Real data: retrospective Italian cohort
Gobbini – WCLC 2018
PFS2 vs . PFS: 29 mo. vs . 14 mo., HR 2.47, p=0.003
(Events registered in 33 patients)